MedTrace Logo

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

NCT04637204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1540

Last updated 2021-02-01

No results posted yet for this study

Summary

The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).

Conditions

Interventions

DRUG

Cabozantinib

oral therapy

DRUG

Axitinib

oral therapy

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-24
Primary Completion
2020-12-11
Completion
2020-12-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04637204 on ClinicalTrials.gov